Evidence map›Paper›PMID 37924649›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2023

Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities.

Kari Leung, Megan McLeod, Julie Torode, André Ilbawi, Jade Chakowa, Brian Bourbeau, Manju Sengar, Christopher M Booth, Julie R Gralow, Richard Sullivan and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kari LeungDepartment of Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK. Electronic address: kari.leung@nhs.net.
Megan McLeodVanderbilt University School of Medicine, Nashville, Tennessee, USA.
Julie TorodeInstitute of Cancer Policy, King's College London, London, UK.
André IlbawiWorld Health Organization, Geneva, Switzerland.
Jade ChakowaCity Cancer Challenge, Geneva, Switzerland.
Brian BourbeauAmerican Society of Clinical Oncology, Alexandria, Virginia, USA.
Manju SengarDepartment of Medical Oncology, Tata Memorial Centre, Mumbai, India.
Christopher M BoothDivision of Cancer Care and Epidemiology, Departments of Oncology and Public Health, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Julie R GralowAmerican Society of Clinical Oncology, Alexandria, Virginia, USA.
Richard SullivanInstitute of Cancer Policy, King's College London, London, UK.
Ajay AggarwalDepartment of Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeThe number of systemic anticancer therapy (SACT) regimens has expanded rapidly over the last decade. There is a need to ensure quality of SACT delivery across cancer services and systems in different resource settings to reduce morbidity, mortality, and detrimental economic impact at individual and systems level. Existing literature on SACT focuses on treatment efficacy with few studies on quality or how SACT is delivered within routine care in comparison to radiation and surgical oncology.

methodsSystematic review was conducted following PRISMA guidelines. EMBASE and MEDLINE were searched and handsearching was undertaken to identify literature on existing quality indicators (QIs) that detect meaningful variations in the quality of SACT delivery across different healthcare facilities, regions, or countries. Data extraction was undertaken by two independent reviewers.

resultsThis review identified 63 distinct QIs from 15 papers. The majority were process QIs (n = 55, 87.3%) relating to appropriateness of treatment and guideline adherence (n = 28, 44.4%). There were few outcome QIs (n = 7, 11.1%) and only one structural QI (n = 1, 1.6%). Included studies solely focused on breast, colorectal, lung, and skin cancer. All but one studies were conducted in high-income countries.

conclusionsThe results of this review highlight a significant lack of research on SACT QIs particularly those appropriate for resource-constrained settings in low- and middle-income countries. This review should form the basis for future work in transforming performance measurement of SACT provision, through context-specific QI SACT development, validation, and implementation.

Indexed as

Quality Indicators, Health CareSkin NeoplasmsBenchmarkingDelivery of Health CareHumansTreatment OutcomeQuality improvementQuality indicatorQuality of careSystemic anticancer therapy

Identifiers

PMID37924649
PMCPMC10697827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.